Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib Rollover Study in Advanced Solid Tumors
NCT03040973Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
A Phase 2 trial of capmatinib in solid tumor (advanced stage), sponsored by Novartis. Started Jul 2017; status: active, not recruiting.
02
Drugs
capmatinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03040973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040973.